Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cancer Treatment Reviews

• Publication date

  2014-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.ctrv.2013.11.005PMID 24315741
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The basic principles of chimeric antigen receptor design.

  2013cited by this paper
• Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

  2013cited by this paper
• Nivolumab plus ipilimumab in advanced melanoma.

  2013cited by this paper
• Activated tumor‐infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer

  2013cited by this paper
• Stromal galectin-1 expression is associated with long-term survival in resectable pancreatic ductal adenocarcinoma

  2012cited by this paper
• The expressions and clinical significances of tissue and serum galectin-3 in pancreatic carcinoma

  2012cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Effect of Pemetrexed on Innate Immune Killer Cells and Adaptive Immune T Cells in Subjects With Adenocarcinoma of the Pancreas

  2012cited by this paper
• B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.

  2012cited by this paper
• Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients.

  2012cited by this paper
• Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance.

  2012cited by this paper
• A randomized, placebo-controlled, double blind, multicenter phase II adjuvant trial of the efficacy, immunogenicity, and safety of GI-4000 plus gem versus gem alone in patients with resected pancreas cancer with activating RAS mutations/survival and immunology analysis of the R1 subgroup.

  2012cited by this paper
• Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response.

  2012cited by this paper
• Overexpressed Galectin-3 in Pancreatic Cancer Induces Cell Proliferation and Invasion by Binding Ras and Activating Ras Signaling

  2012cited by this paper
• High expression of Galectin‐1 in pancreatic stellate cells plays a role in the development and maintenance of an immunosuppressive microenvironment in pancreatic cancer

  2012cited by this paper
• T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice.

  2012cited by this paper
• Differentiation and gene expression profile of tumor-associated macrophages.

  2012cited by this paper
• Circulating CD4+CD25+ Regulatory T Cells in Patients With Pancreatic Cancer

  2012cited by this paper
• Circulating myeloid dendritic cells as prognostic factors in patients with pancreatic cancer who have undergone surgical resection.

  2012cited by this paper
• Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13

  2011cited by this paper
• Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells.

  2011cited by this paper
• Long‐term follow‐up of patients with resected pancreatic cancer following vaccination against mutant K‐ras

  2011cited by this paper
• Significance of M2-polarized tumor-associated macrophage in pancreatic cancer.

  2011cited by this paper
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

  2011cited by this paper
• The CD40‐CD154 interaction would correlate with proliferation and immune escape in pancreatic ductal adenocarcinoma

  2011cited by this paper
• Clinical significance of the immunostimulatory MHC class I chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer

  2011cited by this paper
• CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

  2011influential reference
• A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma: A Phase II Trial of Safety, Efficacy, and Immune Activation

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• Targeting Mutated K-ras in Pancreatic Adenocarcinoma Using an Adjuvant Vaccine

  2011cited by this paper
• Multiple functional targets of the immunoregulatory activity of galectin-1: Control of immune cell trafficking, dendritic cell physiology, and T-cell fate.

  2010cited by this paper
• Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity

  2010cited by this paper
• Tim-3/Galectin-9 Pathway: Regulation of Th1 Immunity through Promotion of CD11b+Ly-6G+ Myeloid Cells

  2010cited by this paper
• Semi Mature Blood Dendritic Cells Exist in Patients with Ductal Pancreatic Adenocarcinoma Owing to Inflammatory Factors Released from the Tumor

  2010cited by this paper
• Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Clinical Significance of B7-H1 and B7-1 Expressions in Pancreatic Carcinoma

  2010cited by this paper
• Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

  2010cited by this paper
• Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis.

  2010cited by this paper
• Identification of up- and down-regulated proteins in gemcitabine-resistant pancreatic cancer cells using two-dimensional gel electrophoresis and mass spectrometry.

  2010cited by this paper
• Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner.

  2010cited by this paper
• Faculty Opinions recommendation of Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha.

  2010cited by this paper
• Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer

  2009cited by this paper
• Clinical Use of Anti‐CD25 Antibody Daclizumab to Enhance Immune Responses to Tumor Antigen Vaccination by Targeting Regulatory T cells

  2009cited by this paper
• Dynamic Behavior and Function of Foxp3+ Regulatory T Cells in Tumor Bearing Host

  2009cited by this paper
• Clinical importance of B7-H3 expression in human pancreatic cancer

  2009cited by this paper
• A randomized phase III study of gemcitabine (G) versus GV1001 in sequential combination with G in patients with unresectable and metastatic pancreatic cancer (PC).

  2009cited by this paper
• Role of macrophages in tumour progression.

  2009cited by this paper
• Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.

  2009cited by this paper
• Increase in frequency of myeloid‐derived suppressor cells in mice with spontaneous pancreatic carcinoma

  2009cited by this paper
• Tumor-associated galectin-3 modulates the function of tumor-reactive T cells.

  2008cited by this paper
• Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes.

  2008influential reference
• PROTEOMIC ANALYSIS TO IDENTIFY BIOMARKER PROTEINS IN PANCREATIC DUCTAL ADENOCARCINOMA

  2008cited by this paper
• Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection.

  2008cited by this paper
• B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression

  2008cited by this paper
• Carcinoembryonic Antigen-Specific but Not Antiviral CD4+ T Cell Immunity Is Impaired in Pancreatic Carcinoma Patients1

  2008cited by this paper
• A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors.

  2008cited by this paper
• Cancer-related inflammation

  2008cited by this paper
• Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1.

  2008cited by this paper
• Effective Depletion of Regulatory T Cells Allows the Recruitment of Mesothelin‐Specific CD8+ T Cells to the Antitumor Immune Response Against a Mesothelin‐Expressing Mouse Pancreatic Adenocarcinoma

  2008cited by this paper
• Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer.

  2007cited by this paper
• Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer

  2007cited by this paper
• Loss of expression of antigen‐presenting molecules in human pancreatic cancer and pancreatic cancer cell lines

  2007cited by this paper
• Costimulation, coinhibition and cancer.

  2007cited by this paper
• The Combined Effects of Tryptophan Starvation and Tryptophan Catabolites Down-Regulate T Cell Receptor ζ-Chain and Induce a Regulatory Phenotype in Naive T Cells1

  2006cited by this paper
• Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study

  2006cited by this paper
• Clinical Roles of Increased Populations of Foxp3+CD4+ T Cells in Peripheral Blood from Advanced Pancreatic Cancer Patients

  2006cited by this paper
• Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes

  2006cited by this paper
• Prevalence of FOXP3+ Regulatory T Cells Increases During the Progression of Pancreatic Ductal Adenocarcinoma and Its Premalignant Lesions

  2006cited by this paper
• Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival

  2006cited by this paper
• TGF-beta1 down-regulates ICAM-1 expression and enhances liver metastasis of pancreatic cancer.

  2006cited by this paper
• Inability of a Fusion Protein of IL-2 and Diphtheria Toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to Eliminate Regulatory T Lymphocytes in Patients With Melanoma

  2005cited by this paper
• Immunosuppressive networks in the tumour environment and their therapeutic relevance

  2005cited by this paper
• High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients.

  2005cited by this paper
• Galectin-1 is an inductor of pancreatic stellate cell activation.

  2005cited by this paper
• Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.

  2005cited by this paper
• Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma

  2004cited by this paper
• CD8+ Tumor-Infiltrating Lymphocytes Together with CD4+ Tumor-Infiltrating Lymphocytes and Dendritic Cells Improve the Prognosis of Patients with Pancreatic Adenocarcinoma

  2004cited by this paper
• Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes

  2004cited by this paper
• Circulating anti‐MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer

  2003cited by this paper
• Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation.

  2001cited by this paper
• TGF-beta1 promotes liver metastasis of pancreatic cancer by modulating the capacity of cellular invasion.

  2001cited by this paper
• Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients.

  1999cited by this paper
• Natural killer cell activity in patients with adenocarcinoma in the upper gastrointestinal tract.

  1991cited by this paper
• Journal of Translational Medicine Transient T Cell Depletion Causes Regression of Melanoma Metastases

  year unknowncited by this paper

• Cystic lesions and their role in pancreatic cancer risk stratification.

  2026cites this paper
• Prognostic value of nutrition and inflammation based scores in patients with metastatic pancreatic cancer

  2026cites this paper
• Research progress on the influence of tumor microenvironment on immunotherapy for pancreatic ductal adenocarcinoma

  2026cites this paper
• Chimeric Collagen-like Proteins with Tunable Structural Heterogeneity for Precise Control and Targeted Doxorubicin Delivery

  2025cites this paper
• Downregulation of the CCK-B Receptor in Pancreatic Stellate Cells Blocks Molecular Proliferative Pathways and Increases Apoptosis to Decrease Pancreatic Cancer Growth In Vitro

  2025cites this paper
• Immunogenicity and safety of COVID-19 vaccines in patients with pancreatic cancer.

  2025cites this paper
• Polysaccharide Fraction Isolated from Saccharina japonica Exhibits Anti-Cancer Effects Through Immunostimulating Activities

  2025cites this paper
• Immune cell changes following chemotherapy in advanced pancreatic cancer with variations based on gender

  2025cites this paper
• Molecular insights into immune evasion and therapeutic paradigms in pancreatic cancer.

  2025cites this paper
• Paradoxical effects of adiposity and inflammation on immunotherapy efficacy in gastric cancer: novel insights from real-world data

  2025cites this paper
• Mucosal-associated invariant T-cells in pulmonary pathophysiology

  2025cites this paper
• Structural characterization of rhamnogalacturonan-I purified from Curcuma longa and its anti-lung cancer efficacy via immunostimulation

  2024cites this paper
• Challenges and Opportunities in Targeting the Complex Pancreatic Tumor Microenvironment

  2024cites this paper
• Immune cells and checkpoints in pancreatic adenocarcinoma: Association with clinical and pathological characteristics

  2024cites this paper
• Jingfang Granules May Improve Early Pancreatic Cancer by Modulating Immune Response Through RUNX3

  2024cites this paper
• Addition of losartan to FOLFIRINOX and chemoradiation reduces immunosuppression-associated genes, Tregs and FOXP3+ cancer cells in locally advanced pancreatic cancer.

  2023cites this paper
• Spatial genomics reveals a high number and specific location of B cells in the pancreatic ductal adenocarcinoma microenvironment of long-term survivors

  2023influential citation
• Overexpression of the adhesion signaling pathway is linked to short-term survival in pancreatic ductal adenocarcinoma.

  2023cites this paper
• Therapeutic Approaches in Pancreatic Cancer: Recent Updates

  2023cites this paper
• An amino acid metabolism-based seventeen-gene signature correlates with the clinical outcome and immune features in pancreatic cancer

  2023cites this paper
• Cholecystokinin Receptor Antagonist Induces Pancreatic Stellate Cell Plasticity Rendering the Tumor Microenvironment Less Oncogenic

  2023cites this paper
• Deletion of the mRNA stability factor ELAVL1 (HuR) in pancreatic cancer cells disrupts the tumor microenvironment integrity

  2023cites this paper
• Decreased survival in patients with pancreatic cancer may be associated with an increase in histopathological expression of inflammasome marker NLRP3.

  2023cites this paper
• Immunostimulating activities and anti-cancer efficacy of rhamnogalacturonan-I rich polysaccharide purified from Panax ginseng leaf

  2023cites this paper
• The association between CD3+ and CD8+tumor-infiltrating lymphocytes (TILs) and prognosis in patients with pancreatic adenocarcinoma.

  2023cites this paper
• Perioperative oncolytic virotherapy to counteract surgery-induced immunosuppression and improve outcomes in pancreatic ductal adenocarcinoma

  2023influential citation
• Construction of a cuproptosis-associated long non-coding RNA risk prediction model for pancreatic adenocarcinoma based on the TCGA database

  2023cites this paper
• Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison to established serum tumor markers

  2022cites this paper
• Fat-Soluble Vitamin Deficiencies and Disruption of the Immune System in Pancreatic Cancer

  2022cites this paper
• Interplay of four types of RNA modification writers revealed distinct tumor microenvironment and biological characteristics in pancreatic cancer

  2022cites this paper
• Editorial: Identification of novel biomarkers for pancreatic and hepatocellular cancers

  2022cites this paper
• The antitumor activity of hPRDX5 against pancreatic cancer and the possible mechanisms

  2022cites this paper
• Addition of losartan to FOLFORINOX and chemoradiation downregulates pro-invasion and immunosuppression-associated genes in locally advanced pancreatic cancer

  2022influential citation
• Immunotherapy in pancreatic cancer-an emerging role: a narrative review.

  2022cites this paper
• Clinical Implication of Preoperative C-Reactive Protein/Albumin Ratio in Malignant Transformation of Intraductal Papillary Mucinous Neoplasm: A Propensity Score Analysis

  2022cites this paper
• Systemic Immune-Inflammation Index and Changes of Neutrophil-Lymphocyte Ratio as Prognostic Biomarkers for Patients With Pancreatic Cancer Treated With Immune Checkpoint Blockade

  2021cites this paper
• The Unique Microbiome and Immunity in Pancreatic Cancer

  2021cites this paper
• The Match between Molecular Subtypes, Histology and Microenvironment of Pancreatic Cancer and Its Relevance for Chemoresistance

  2021cites this paper
• Successful Immunotherapy for Pancreatic Cancer in a Patient With TSC2 and SMAD4 Mutations: A Case Report

  2021cites this paper
• Towards an updated view on the clinical management of pancreatic adenocarcinoma: Current and future perspectives

  2021cites this paper
• The long non-coding RNA DKFZp434J0226 regulates the alternative splicing process through phosphorylation of SF3B6 in PDAC

  2021cites this paper
• Peripheral Blood Lymphocyte Percentage May Predict Chemotolerance and Survival in Patients with Advanced Pancreatic Cancer. Association between Adaptive Immunity and Nutritional State

  2021cites this paper
• Pancreatic Cancer and Immunotherapy: A Clinical Overview

  2021cites this paper
• Irreversible Electroporation and Nivolumab Combined with Intratumoral Administration of a Toll-Like Receptor Ligand, as a Means of In Vivo Vaccination for Metastatic Pancreatic Ductal Adenocarcinoma (PANFIRE-III). A Phase-I Study Protocol

  2021cites this paper
• The Usefulness of Prognostic Nutritional Index in Predicting Infection in Patients with Newly Diagnosed Pancreatic Cancer

  2021cites this paper
• Autoimmune pancreatitis and pancreatic cancer: Epidemiological aspects and immunological considerations

  2021cites this paper
• Development of a novel formulation method to prepare liposomal Epacadostat.

  2021cites this paper
• Identification of LIPH as an unfavorable biomarkers correlated with immune suppression or evasion in pancreatic cancer based on RNA-seq

  2021cites this paper
• Application of natural killer cells in pancreatic cancer.

  2021cites this paper
• Room for improvement in the treatment of pancreatic cancer: Novel opportunities from gene targeted therapy

  2021cites this paper
• Dickkopf-1: A Promising Target for Cancer Immunotherapy

  2021cites this paper
• Irreversible Electroporation (IRE) Combined With Chemotherapy Increases Survival in Locally Advanced Pancreatic Cancer (LAPC)

  2021cites this paper
• Gene coexpression network approach to develop an immune prognostic model for pancreatic adenocarcinoma

  2021cites this paper
• Circulating Protein Biomarkers for Use in Pancreatic Ductal Adenocarcinoma Identification

  2021influential citation
• Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

  2021cites this paper
• Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade

  2020cites this paper
• Oncolytic virotherapy for pancreatic ductal adenocarcinoma: A glimmer of hope after years of disappointment?

  2020cites this paper
• Polyanhydride nanoparticles stabilize pancreatic cancer antigen MUC4β.

  2020cites this paper
• Type I interferons in pancreatic cancer and development of new therapeutic approaches.

  2020cites this paper
• 166 Mucosal-associated invariant T-cells (MAIT) in pancreatic cancer

  2020cites this paper
• Clinical characteristics and surgical treatment of spinal metastases from pancreatic cancer: a single-center retrospective study.

  2020cites this paper
• Dilemma and Challenge of Immunotherapy for Pancreatic Cancer

  2020cites this paper
• The Key Genes for Perineural Invasion in Pancreatic Ductal Adenocarcinoma Identified With Monte-Carlo Feature Selection Method

  2020cites this paper
• Mechanistic target of rapamycin in the tumor microenvironment and its potential as a therapeutic target for pancreatic cancer.

  2020cites this paper
• Exploiting the relevance of CA 19-9 in pancreatic cancer

  2020cites this paper
• Methylation of immune-regulatory cytokine genes and pancreatic cancer outcomes.

  2020cites this paper
• The Science of the Lander College of Arts and Sciences The Science of the Lander College of Arts and Sciences Immunotherapy As a Treatment Option for Patients With Immunotherapy As a Treatment Option for Patients With Pancreatic Cancer Pancreatic Cancer

  2020cites this paper
• Identification of an immune-related long non-coding RNA signature and nomogram as prognostic target for muscle-invasive bladder cancer

  2020cites this paper
• Neutrophil to Lymphocyte Ratio is a Predictive Factor of Malignant Potential for Intraductal Papillary Mucinous Neoplasms of the pancreas

  2019cites this paper
• The Systemic-immune-inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels: A Retrospective Multicenter Cohort Study.

  2019cites this paper
• Beyond the PD-L1 horizon: In search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma.

  2019cites this paper
• Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer

  2019cites this paper
• Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients

  2019cites this paper
• Prognostic Role of the Prognostic Nutritional Index in Pancreatic Cancer: A Meta-analysis

  2019cites this paper
• Inflammation and pancreatic cancer: An updated review

  2019cites this paper
• Inflammation and Pancreatic Cancer: Focus on Metabolism, Cytokines, and Immunity

  2019cites this paper
• Computer-aided assessment of the extra-cellular matrix during pancreatic carcinogenesis: a pilot study

  2019cites this paper
• Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma

  2019cites this paper
• PD-1 immunotherapy in pancreatic cancer: current status

  2019cites this paper
• Bioinformatics profiling utilized a nine immune‐related long noncoding RNA signature as a prognostic target for pancreatic cancer

  2019cites this paper
• Cryopreserved Human Natural Killer Cells Exhibit Potent Antitumor Efficacy against Orthotopic Pancreatic Cancer through Efficient Tumor-Homing and Cytolytic Ability (Running Title: Cryopreserved NK Cells Exhibit Antitumor Effect)

  2019cites this paper
• Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels

  2019cites this paper
• High Systemic Immune-Inflammation Index is an Adverse Prognostic Factor for Patients With Gastroesophageal Adenocarcinoma

  2019cites this paper
• Vaccine Against Gastrin, Polyclonal Antibody Stimulator, Decreases Pancreatic Cancer Metastases.

  2019cites this paper
• Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions

  2019influential citation
• Impact of combination therapy with anti-PD-1 blockade and a STAT3 inhibitor on the tumor-infiltrating lymphocyte status.

  2019cites this paper
• Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma

  2019cites this paper
• 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 2

  2019cites this paper
• The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications

  2019cites this paper
• Xenobiotics and the Gut Microbiome in Health and Disease

  2019cites this paper
• Multifunctional proteases dipeptidyl peptidase-IV and fibroblast activation protein as possible pathogenetic factors, biomarkers and therapeutic targets in cancer

  2018cites this paper
• Role of extracellular vesicles , microvascular fibrin formation and immune surveillance in pancreatic cancer metastasis

  2018cites this paper
• MUC4 Based Immunotherapy for Pancreatic Cancer

  2018influential citation
• From Local to Systemic Treatment: Leveraging Antitumor Immunity Following Irreversible Electroporation

  2018cites this paper
• Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle.

  2018cites this paper
• Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio can predict the severity of gallstone pancreatitis

  2018cites this paper
• Palliative therapy in pancreatic cancer-interventional treatment with radiofrequency ablation/irreversible electroporation.

  2018cites this paper
• Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

  2018cites this paper
• Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options

  2018cites this paper
• Ciblage pharmacologique du microenvironnement de l'adénocarcinome canalaire pancréatique

  2018cites this paper